Literature DB >> 23685362

Elevated serum BAFF levels in patients with sarcoidosis: association with disease activity.

Ikuko Ueda-Hayakawa1, Hirotsugu Tanimura, Manabu Osawa, Hiroshi Iwasaka, Shuichi Ohe, Fumikazu Yamazaki, Kana Mizuno, Hiroyuki Okamoto.   

Abstract

OBJECTIVE: The purpose of this study was to determine serum levels of B-cell-activating factor (BAFF) and its clinical association in patients with sarcoidosis. METHODS; Serum levels of BAFF from 37 patients and 21 healthy subjects were examined by ELISA. Serum angiotensin-converting enzyme (ACE), lysozyme and IFN-γ levels in sarcoidosis patients were also measured. Isolated monocytes cultured with IFN-γ, IL-4 or IL-10 and their expression of membrane and soluble BAFF were analysed by flow cytometry or ELISA. Peripheral B cell subsets were analysed by flow cytometry. BAFF expression in the granuloma of the skin was examined by immunohistochemistry. ANAs were determined by indirect IF using HEp-2 cells as a substrate.
RESULTS: Serum BAFF levels were significantly elevated in sarcoidosis patients when compared with healthy controls. The frequency of skin and eye involvement was significantly higher in patients with elevated serum BAFF than in patients with normal levels. Serum BAFF levels were correlated with serum levels of ACE, lysozyme and IFN-γ. Immunostaining of anti-BAFF in the skin revealed BAFF expression by epithelioid cells of granuloma. In vitro, IFN-γ induced membrane-bound BAFF expression on monocytes and secretion of soluble BAFF by isolated monocytes. In the peripheral blood, sarcoidosis patients showed increased naïve B cells with a reciprocal decrease in memory B cells and plasmablasts. Seventeen of 26 (65%) sarcoidosis patients exhibited ANA positivity.
CONCLUSION: Serum BAFF levels can be used as a surrogate marker of disease activity in sarcoidosis patients. Increased BAFF may be related to the pathogenesis of sarcoidosis.

Entities:  

Keywords:  B cell; B-cell-activating factor (BAFF); monocyte; sarcoidosis

Mesh:

Substances:

Year:  2013        PMID: 23685362     DOI: 10.1093/rheumatology/ket186

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  14 in total

Review 1.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

Review 2.  Using genes to triangulate the pathophysiology of granulomatous autoinflammatory disease: NOD2, PLCG2 and LACC1.

Authors:  Ann Marie Szymanski; Michael J Ombrello
Journal:  Int Immunol       Date:  2018-04-25       Impact factor: 4.823

Review 3.  Potential immunotherapies for sarcoidosis.

Authors:  Van Le; Elliott D Crouser
Journal:  Expert Opin Biol Ther       Date:  2018-01-17       Impact factor: 4.388

4.  Autoantibody profile in sarcoidosis, analysis from the GRADS sarcoidosis cohort.

Authors:  Basheer Khassawneh; Chengsong Zhu; Briana Barkes; Brian Vestal; Sarah Shrock; May Gillespie; Karin Pacheco; Kevin D Deane; Lisa A Maier; Quan-Zhen Li; Nabeel Hamzeh
Journal:  PLoS One       Date:  2022-10-20       Impact factor: 3.752

5.  Significant elevation of the levels of B-cell activating factor (BAFF) in patients with sarcoidosis.

Authors:  Masaru Ando; Akihiko Goto; Yukiko Takeno; Mari Yamasue; Kosaku Komiya; Kenji Umeki; Shin-Ichi Nureki; Eishi Miyazaki; Jun-Ichi Kadota
Journal:  Clin Rheumatol       Date:  2018-06-23       Impact factor: 2.980

Review 6.  Granuloma formation in pulmonary sarcoidosis.

Authors:  Caroline E Broos; Menno van Nimwegen; Henk C Hoogsteden; Rudi W Hendriks; Mirjam Kool; Bernt van den Blink
Journal:  Front Immunol       Date:  2013-12-10       Impact factor: 7.561

Review 7.  Immunopathogenesis of granulomas in chronic autoinflammatory diseases.

Authors:  Wilhelmina Maria Cornelia Timmermans; Jan Alexander Michael van Laar; Petrus Martinus van Hagen; Menno Cornelis van Zelm
Journal:  Clin Transl Immunology       Date:  2016-12-16

8.  Angiotensin II synergizes with BAFF to promote atheroprotective regulatory B cells.

Authors:  Padmapriya Ponnuswamy; Jeremie Joffre; Olivier Herbin; Bruno Esposito; Ludivine Laurans; Christoph J Binder; Thomas F Tedder; Lynda Zeboudj; Xavier Loyer; Andreas Giraud; Yujiao Zhang; Alain Tedgui; Ziad Mallat; Hafid Ait-Oufella
Journal:  Sci Rep       Date:  2017-06-23       Impact factor: 4.379

9.  Correlation of APRIL with production of inflammatory cytokines during acute malaria in the Brazilian Amazon.

Authors:  Raquel A Pinna; Adriana C Dos Santos; Daiana S Perce-da-Silva; Luciene A da Silva; Rodrigo N Rodrigues da Silva; Marcelo R Alves; Fátima Santos; Joseli de Oliveira Ferreira; Josué C Lima-Junior; Déa M Villa-Verde; Paula M De Luca; Carla E Carvalho-Pinto; Dalma M Banic
Journal:  Immun Inflamm Dis       Date:  2018-01-03

10.  Serum B cell activating factor (BAFF) and sarcoidosis activity.

Authors:  Kamila Hashemzadeh; Maryam Fatemipour; Seyede Zahra Mirfeizi; Mohammadhasan Jokar; Zhaleh Shariati Sarabi; Mohammad-Reza Hatef Fard; Houshang Rafatpanah; Mandana Khodashahi
Journal:  Arch Rheumatol       Date:  2020-09-11       Impact factor: 1.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.